SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced that Michael L. Krall, President and CEO, will host a conference call on Thursday, March 12th at 1:30 P.M. PDT to review and discuss second quarter 2009 financial results.
Shareholders and other interested parties may participate in the conference call by dialing 877-407-8033 or (International) 201-689-8033 a few minutes before 1:30 P.M. PDT on March 12th, 2009.
The webcast will be available for replay through June 13th, 2009. A replay of the conference call will be accessible until May 13th, 2009 by dialing 877-660-6853 or (International) 201-612-7415 and entering the Account#: 286 and the Conference ID#: 316499.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
PURE Investor Contact: Paul G. Henning, Vice President Cameron Associates (212) 554-5462 firstname.lastname@example.org
|SOURCE PURE Bioscience|
Copyright©2009 PR Newswire.
All rights reserved